Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Coronary Heart Disease (CHD)

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    71 result(s) found for: Coronary Heart Disease (CHD). Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2012-000191-41 Sponsor Protocol Number: GC28210 Start Date*: 2012-06-19
    Sponsor Name:GENENTECH, Inc.
    Full Title: A PHASE II, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF THE SAFETY AND EFFICACY OF MPSK3169A IN PATIENTS WITH CORONARY HEART DISEASE OR HIGH RISK OF CORONARY HEART DISEASE
    Medical condition: Coronary Heart Disease or High Risk of Coronary Heart Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10068617 Coronary heart disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) CZ (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2012-001989-15 Sponsor Protocol Number: HomRate04_2012 Start Date*: 2012-09-17
    Sponsor Name:Universität des Saarlandes
    Full Title: A randomised, placebo controlled, double blind, cross-over, single center clinical Study to investigate the effect of heart rate reduction with ivabradine on endothelial function and vascular stiff...
    Medical condition: Stable coronary heart disease.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10068617 Coronary heart disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022529-14 Sponsor Protocol Number: WC25501 Start Date*: 2011-02-04
    Sponsor Name:F.Hoffmann-La Roche
    Full Title: A phase III, double-blind, randomized, placebo-controlled, multi-center study evaluating the efficacy and safety of dalcetrapib on lipids, lipoproteins, apolipoproteins and markers of CV risk in pa...
    Medical condition: Coronary Heart Disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10007541 - Cardiac disorders 10068617 Coronary heart disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) NL (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2011-005698-21 Sponsor Protocol Number: EFC11570 Start Date*: 2013-03-05
    Sponsor Name:sanofi-aventis Recherche & Développement
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recentl...
    Medical condition: Acute coronary syndrome
    Disease: Version SOC Term Classification Code Term Level
    19.0 10007541 - Cardiac disorders 10051592 Acute coronary syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) BE (Completed) NO (Completed) EE (Completed) LT (Completed) HU (Completed) ES (Completed) CZ (Completed) LV (Completed) DE (Completed) IT (Completed) BG (Completed) FI (Completed) AT (Completed) PT (Completed) DK (Completed) NL (Completed) PL (Completed) SK (Completed) SI (Completed) HR (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2005-003013-32 Sponsor Protocol Number: GE IDE No. A01005 Start Date*: 2005-11-08
    Sponsor Name:Deutsches Herzzentrum München
    Full Title: PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED; MULTICENTER TRIAL OF BIVALIRUDIN AND UN-FRACTIONATED HEPARIN IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS
    Medical condition: Coronary Artery Disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10011099 Coronary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-005575-96 Sponsor Protocol Number: LPL100601 Start Date*: 2008-11-26
    Sponsor Name:GlaxoSmithKline Research & Development, Ltd
    Full Title: A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
    Medical condition: chronic Coronary Heart Disease (cCHD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) ES (Completed) HU (Completed) SE (Completed) DE (Completed) GB (Completed) SK (Completed) FR (Completed) DK (Completed) EE (Completed) BE (Completed) CZ (Completed) PL (Completed) BG (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2007-002427-32 Sponsor Protocol Number: TCA-01-III Start Date*: 2008-07-16
    Sponsor Name:UNIVERSITA' DEGLI STUDI DI FERRARA
    Full Title: Ajuste del tratamiento con tirofibán en pacientes que presentan resistencia a la aspirina o al clopidogrel: 3T/2R Tailoring Treatment with Tirofiban in patients showing Resistance to aspirin and/o...
    Medical condition: Pacientes con enfermedad coronaria que van a someterse a una intervención coronaria percutánea. Patients with coronary disease undergoing percutaneous coronary intervention
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011099 Coronary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000457-36 Sponsor Protocol Number: 14-006 Start Date*: 2015-03-10
    Sponsor Name:CHU CAEN
    Full Title: A comparative dynamic study of myocardial perfusion reserve explored by cardiac WATER labelled O-15 -PET vs Tc99mibi D-SPECT in coronAry arterY disease. Protocol WATER -DAY
    Medical condition: Patient suspect d’une maladie coronaire et/ou syndrome coronarien ST-
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004849 10011099 Coronary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2004-000156-16 Sponsor Protocol Number: A509 1043 Start Date*: 2004-09-14
    Sponsor Name:Pfizer AB
    Full Title: Phase 3 multi center, double blind, randomized, parallel group evaluation of the fixed combination torcetrapib/atorvastatin, administered orally, once daily (QD), compared with atorvastatin alone, ...
    Medical condition: Coronary Heart Disease
    Disease: Version SOC Term Classification Code Term Level
    10011078
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) ES (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-012206-39 Sponsor Protocol Number: ALX-0081-2.1/09 Start Date*: 2009-08-14
    Sponsor Name:Ablynx
    Full Title: A phase II randomized, open label clinical trial in high risk percutaneous coronary intervention (PCI) patients receiving standard antithrombotic treatment plus either ALX-0081 or GPIIb/IIIa inhibi...
    Medical condition: Thrombotic events associated with percutaneous coronary intervention (PCI) in patients with unstable angina or Non ST-Segment Elevation Myocardial Infarction (NSTEMI), or stable angina with at leas...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011076 Coronary artery atherosclerosis LLT
    9.1 10011078 Coronary artery disease LLT
    9.1 10013210 Disorder coronary artery LLT
    9.1 10063933 Coronary stent thrombosis LLT
    9.1 10065608 Percutaneous coronary intervention LLT
    9.1 10003211 Arteriosclerosis coronary artery LLT
    9.1 10011067 Coronary angiogram abnormal LLT
    9.1 10011093 Coronary atherosclerosis LLT
    9.1 10011099 Coronary disease LLT
    9.1 10051592 Acute coronary syndrome LLT
    9.1 10011076 Coronary artery atherosclerosis LLT
    9.1 10011093 Coronary atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) CZ (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004565-14 Sponsor Protocol Number: 20170625 Start Date*: 2019-09-13
    Sponsor Name:Amgen Inc.
    Full Title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardia...
    Medical condition: Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004861 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) SE (Trial now transitioned) HU (Trial now transitioned) DK (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) BG (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) FI (Trial now transitioned) AT (Trial now transitioned) LT (Trial now transitioned) LV (Trial now transitioned) EE (Trial now transitioned) SK (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned) IS (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-024044-15 Sponsor Protocol Number: BMS747158-301 Start Date*: 2011-06-08
    Sponsor Name:Lantheus Medical Imaging, Inc.
    Full Title: A Phase 3, Open-Label, Multicenter Study for the Assessment of Myocardial Perfusion using Positron Emission Tomography (PET) Imaging of Flurpiridaz F 18 Injection in Patients with Suspected or Know...
    Medical condition: Assessment of myocardial perfusion using Positron Emission Tomography (PET) Imaging of Flurpiridaz F 18 Injection in patients with suspected or known coronary artery disease.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004849 10068617 Coronary heart disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002678-29 Sponsor Protocol Number: BMS747158-302 Start Date*: 2013-02-21
    Sponsor Name:Lantheus Medical Imaging, Inc.
    Full Title: A Phase 3, Open-Label, Multicenter Study for the Assessment of Myocardial Perfusion using Positron Emission Tomography (PET) Imaging of Flurpiridaz F 18 Injection in Patients with Suspected or Know...
    Medical condition: Assessment of myocardial perfusion using Positron Emission Tomography (PET) Imaging of Flurpiridaz F 18 Injection in patients with suspected or known coronary artery disease.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004849 10068617 Coronary heart disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005628-17 Sponsor Protocol Number: TCC0205 Start Date*: 2008-02-22
    Sponsor Name:GRUPO DE TERAPIA CELULAR Y CARDIOVASCULAR DEL HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS
    Full Title: Estudio abierto con evaluador ciego de la eficacia de las células mononucleares autólogas de médula ósea en la regeneración muscular y vascular en pacientes con disfunción ventricular izquierda tra...
    Medical condition: TRATAMIENTO DE ENFERMEDAD CORONARIA (IAM Y DISFUNCIÓN VENTRICULAR IZQUIERDA / TREATMENTOF CORONARY DISEASE (AMI AND LEFT VENTRICULAR DYSFUNTION)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011099 Coronary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-002650-38 Sponsor Protocol Number: Pre65 Start Date*: 2008-07-01
    Sponsor Name:Organisation name was not entered
    Full Title: Vähentääkö pregabaliini opioidikipulääkityksen tarvetta ja kroonisen kivun esiintyvyyttä alle 65-vuotiailla potilailla sydänleikkauksen jälkeen?
    Medical condition: Tutkimukseen otetaan potilaan suostumuksella alle 65-vuotiaita avosydänleikkauk-seen joko koronaariohitus- tai sydämen läppärekonstruktioon tulevia potilaita, jotka leikatataan perfuusioleikkauksena.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011099 Coronary disease LLT
    9.1 10002906 Aortic stenosis LLT
    9.1 10027716 Mitral insufficiency LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004901-91 Sponsor Protocol Number: P070117 Start Date*: 2008-02-25
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Exploration de l'influence du polymorphisme *2 du gène codant pour le cytochrome 2C19 sur la réponse au clopidogrel chez le jeune coronarien
    Medical condition: Les patients inclus dans cette étude seront issus de la cohorte AFIJI (Architecture de la FIbrine chez les Jeunes coronariens Ischémiques)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10011099 Coronary disease PT
    Population Age: Adults Gender: Male
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-019154-40 Sponsor Protocol Number: DOSAPI Start Date*: 2010-05-19
    Sponsor Name:Medco Health Solutions, Inc.
    Full Title: Doubler la dose du clopidogrel ou passer au Prasugrel pour contrer l’interaction liée aux inhibiteurs de pompe à protons
    Medical condition: Maladie des artères coronaires
    Disease: Version SOC Term Classification Code Term Level
    12.1 10011099 Coronary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002535-12 Sponsor Protocol Number: kimcl2004-08 Start Date*: 2004-11-19
    Sponsor Name:Clinical Institute of Medical and Chemical Laboratory Diagnostics Graz
    Full Title: Fluvastatin 80 mg ret. vs combination with ezetimib 10 mg
    Medical condition: elevated LDL-C
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000504-18 Sponsor Protocol Number: A01711 Start Date*: 2011-05-10
    Sponsor Name:Deutsches Herzzentrum München, Klinik für Herz- und Kreislauferkrankungen
    Full Title: DABI-ADP-2: IMPACT OF DABIGATRAN AND PHENPROCOUMON ON CLOPIDOGREL MEDIATED ADP INDUCED PLATELET AGGREGATION IN PATIENTS WITH ATRIAL FIBRILLATION
    Medical condition: Patients with atrial fibrillation and in indication for oral anticoagulation, who are currently receiving additionally clopidogrel for another medical condition, such as acute coronary syndrome and...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10068617 Coronary heart disease LLT
    14.1 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    14.1 10007541 - Cardiac disorders 10051592 Acute coronary syndrome PT
    14.1 10047065 - Vascular disorders 10003601 Atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-012581-32 Sponsor Protocol Number: SB-480848/033 Start Date*: 2010-01-28
    Sponsor Name:GlaxoSmithKline Research & Development, Ltd
    Full Title: A Clinical Outcomes Study of Darapladib versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE). (Short title: The Stabi...
    Medical condition: after recent Acute Coronary Syndrome (ACS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10051592 Acute coronary syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BE (Completed) ES (Completed) NL (Completed) SE (Completed) DK (Completed) HU (Completed) CZ (Completed) SK (Completed) PL (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 09:48:55 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA